and HIV management remain scarce. 69
Methods

70
In this prospective study, we describe the TB treatment regimens of patients with multi-drug resistant 71 (MDR) TB and use of antiretroviral therapy (ART). 72
Results
73
A total of 105 HIV-positive patients had MDR-TB (including 33 with extensive drug resistance) and 130 pan-74 susceptible TB. Adequate initial TB treatment was provided for 8% of patients with MDR-TB compared with 75 80% of those with pan-susceptible TB. By twelve months, an estimated 57.3% (95%CI 41.5-74.1) of MDR-TB 76 patients had started adequate treatment. While 67% received ART, HIV-RNA suppression was 77 demonstrated in only 23%. 78
Conclusions 79
Our results show that internationally recommended MDR-TB treatment regimens were infrequently used 80 and that ART use and viral suppression was well below the target of 90%, reflecting the challenging patient 81 population and the environment in which health care is provided. Urgent improvement of management of 82 Introduction 87 Although rates of tuberculosis (TB) have begun to decline in recent years, simultaneous rapid increases in 88 the relative contribution of multi-drug resistant TB (MDR-TB) and extensively drug resistant TB (XDR-TB) are 89 worrying (1) (2) (3) (4) . Eastern Europe (EE), together with central Asia, has the worlds' highest proportions of and XDR-TB with 9-35% of new TB cases and 49-77% of re-treatment cases being diagnosed with MDR-TB in 91
Belarus, Russia and Ukraine compared with 1-3% of new cases and 4-14% of re-treatment cases in Italy, 92 Switzerland and the United Kingdom (1, (5) (6) (7) (8) . 93
The MDR-TB epidemic in EE is further complicated by high rates of HIV co-infection. Whereas most other 94 regions have reported declining rates of new HIV infections over recent years, EE has experienced an 95 increase of 30% in annual number of new HIV infections since the turn of the millennium (9, 10). The 96 TB/HIV epidemic in EE is primarily driven by injection drug users (IDU) who often access health care late, 97 are co-infected with hepatitis C (HCV), and frequently have poor treatment compliance and retention in 98 care (11) (12) (13) (14) . We recently reported a one-year mortality rate of 27% for TB/HIV co-infected patients in EE, 99 and patients diagnosed with MDR-TB had roughly three-times higher mortality compared to those with 100 drug-susceptible TB. Further, patients from EE who initiated TB treatment with three or more active drugs 101 had significantly lower risk of death compared to patients who received less than three active TB drugs 102 (13% vs 34%) (15) . 103
Treatment for MDR-TB is complex in terms of pill burden, drug-interactions and toxicity, and costly (1, an option for shorter MDR-TB regimens in specific cases (16, 19) . Preliminary results with a novel six 106 months regimen (consisting of pretomanid, bedaquiline and linezolid) may be highly effective to treat . For now, standard of care consists of at least five drugs including a fluoroquinolone, a second-line 108 injectable, at least two other active drugs plus pyrazinamide during the intensive phase of treatment (19) . 109
Reported MDR-TB treatment success rates, however, have been generally low, in particular for HIV-positive 110 individuals, and rarely exceed 50% (18, 21) . 111
Epidemiological data and detailed descriptions of the clinical management of HIV-positive patients with 112 MDR-TB in EE remain relatively scarce (22). We prospectively studied patients with TB/HIV co-infection in 113 EE and in this paper report on the management of those with MDR-TB. 114
115
Methods
116
Study design and participants 117
The TB:HIV Study is a prospective cohort study including 62 TB and HIV clinics in 19 countries in EE, Western 118 Europe, Southern Europe, and Latin America. Adult (>16 years) HIV-positive patients with a TB diagnosis 119 were consecutively enrolled between 01/01/2011 and 31/12/2013. Demographic, clinical, and laboratory 120 data were collected on standardized case report forms at baseline and month 6, 12, and 24 (12); further 121 details are available at http://www.cphiv.dk/TBHIV. All participating clinics obtained ethical approval in 122 accordance with local rules and legislations, and the study was performed in accordance with the strobe 123 guidelines for observational studies (23). 124
Study definitions 125
Patients from EE were included in the present analyses if they had definite or probable TB. A diagnosis of 126 definite TB was based on positive culture or molecular diagnostics for Mycobacterium tuberculosis (Mtb), 127 and probable TB on the presence of acid fast bacilli and/or granulomatous inflammation on sputum smear 128 or tissue biopsy specimens (12). Baseline was defined as the date TB treatment was initiated, and a 129 baseline culture was defined as a culture obtained within one month of baseline. All TB drugs initiated 130 within 10 days of baseline were considered to constitute initial TB treatment. Standard definitions of MDR-131 TB, pre-XDR-TB, and XDR-TB were used (see box), and pan-susceptible TB was defined as TB without 132 documented drug resistance. TB treatment regimens were categorized in line with general 133 recommendations (16, 24): 1: Treatment regimens containing RHZ (with or without ES) targeting drug-134 susceptible TB (24), 2: Treatment regimens containing RHZ plus a fluoroquinolone AND a second line 135 injectable, providing empiric cover for both susceptible TB and MDR-TB, 3: Five or more MDR-TB drugs 136 (including a fluoroquinolone AND a second line injectable) providing appropriate empiric cover for MDR-TB, 137 4: Regimens containing a fluoroquinolone OR a second line injectable (but not both), providing inadequate 138 cover for MDR-TB , and 5: Any other drug combination ( Fig. 1 ). For patients with MDR-TB, the number of 139 active drugs in the TB regimen was calculated at various time points based on the susceptibility pattern of 140 isolates obtained up to the given time point. If a Drug Susceptibility Test (DST) result was not available for a 141 specific drug included in the regimen, the given Mtb isolate was either considered potentially susceptible to 142 this drug (potentially active drugs) or resistant to this drug (known active drugs), thus representing a "best 143 case" and "worst case" treatment scenario. 144 Antiretroviral treatment (ART) was defined as a combination of >3 antiretroviral drugs from any ART class. 145
Participants were considered lost to follow-up (LTFU) when no attendance was recorded at the relevant 146 time points in those who were not known to have died. 147
Statistical analysis 148
Descriptive statistics were used for baseline characteristics of patients. Patients were stratified into three 149 groups: MDR-TB at baseline, pan-susceptible TB at baseline, and other (no baseline DST results available or 150 the presence of non-MDR-TB resistance patterns). MDR-TB patients who had extended DST available were 151 further classified as having pre-XDR or XDR-TB. Baseline characteristics among patients who had MDR-TB, 152 those who were fully susceptible and those who did not have any baseline DST available were compared 153 using the chi-squared test or Fisher's exact test as appropriate for categorical variables, whereas the 154 Kruskal-Wallis test was used to compare continuous variables. 155 TB and HIV treatment regimens were analyzed at months 0, 3, 7, 13, and 21. Kaplan-Meier estimates were 156 used to estimate time to receiving adequate treatment for MDR-TB (category 3: five or more MDR-TB drugs 157 including a fluoroquinolone AND a second line injectable), and time to starting ART censoring at last visit 158 date (maximum 21 months) or death, whichever occurred first. Further, Kaplan-Meier estimates were also 159 used to estimate the time to starting ART. All statistical analyses were performed using SAS (Statistical 160 Analysis Software, Cary, NC, USA, version 9.3). 161
162
Results
163
Patient characteristics 164
Of 1406 patients enrolled into the TB:HIV study, 834 received care in EE, of these 485 had definite or 165 probable TB and were included in this analysis (supplementary Fig. 1) . A positive culture for Mtb was 166 reported in 383 (79%) patients, 302 (79%) of these were tested for resistance to any drug, 270 (70%) for 167 both R and H, and 68 (18%) for fluoroquinolone or second line injectables. Of the 485 patients, 105 (22%) 168 had MDR-TB, 130 (27%) had pan-susceptible TB at baseline and 183 (38%) had no DST results; the 169 remaining 67 (14%) had non-MDR-TB resistance patterns and were excluded from subsequent analyses. 170
Baseline characteristics are shown in Table 1 . The majority of patients were male and white, with a median 171 age of 35 years. Recent incarceration was common, and previous TB, IDU, and HCV co-infection were 172 significantly more common among MDR-TB patients. The median baseline CD4 cell count was 91 173 (interquartile range [IQR] 31-230) cells/mm 3 , and only 82 (17%) patients were on ART.
DST patterns for MDR-TB patients 175
Among the 105 patients with MDR-TB at baseline, DST results (obtained at any time during TB treatment) 176 for other drugs ranged from 51-95% for group 1 drugs, 75-78% for group 2/3 drugs, and 49-69% for group 4 177 drugs ( Table 2 ). The timing of DST testing for individual TB drugs is shown in Table 3a . Overall, 13 (12%) of 178 MDR-TB patients had XDR-TB, 20 (19%) had pre-XDR, 35 (33%) had MDR, and 37 patients had insufficient 179 data to determine pre-XDR/XDR-TB status. "known" active drugs, respectively, in the MDR-TB treatment regimens. While most patients received 4 or 204 more drugs in their regimen during the first year of treatment, more than 70% received 0, 1 or 2 drugs with 205 demonstrated activity. A regimen containing 5 or more known active drugs was received by less than 15% 206 of patients and a regimen containing 5 or more potentially active drugs by less than 40% of patients. 207
HIV treatment for MDR-TB patients 208
Despite 77% of MDR-TB patients at the time of their TB diagnosis already having an HIV diagnosis and the 209 majority being severely immunosuppressed with a median CD4 cell count of 100 cells/mm 3 , only 13% were 210 on ART at baseline ( Table 1 ). The proportion on ART among those who remained in care increased to more 211 than 60% (Figure 3 ). The majority of those on ART did not have regular HIV-RNA monitoring, and less than 212 20% of MDR-TB patients were documented to have had an undetectable HIV-RNA (<500 copies/mL) at any 213 stage during follow up. The Kaplan-Meier estimate of starting ART by eight weeks was only 23%; similar 214 results were observed for patients with drug-susceptible TB and those with no DST results (data not 215 shown). the patients with MDR-TB, approximately one-third had MDR, one-third had pre-XDR or XDR-TB, and one-232 third did not have sufficient DST data to assess whether they had (pre-)XDR-TB. We also found common co-233 resistance to other drugs, as described in another European multicenter study (27) . Despite the setting of 234 high MDR-TB prevalence in EE, empiric therapy rarely provided cover for MDR-TB. This is also problematic 235 as selection for additional drug-resistance is more likely to occur early on when the bacillary burden is high. 236
It is worth noting, however, that four in five patients who later were shown to have fully susceptible TB, 237 initially received adequate RHZ-based treatment, as recently described (28). 238
In patients with MDR-TB, there were significant delays to initiate treatment for MDR-TB, and many patients 239 never received adequate MDR-TB treatment as defined by international guidelines (19). The number of 240 active drugs remained low at all time points; only one-third of patients were treated at some stage with at 241 least five potentially active drugs, and only one-sixth of patients received regimens with 5 drugs known to 242 have activity against their Mtb isolate. This is of concern as recent studies demonstrate improved outcomes 243 with optimal MDR-TB regimens (≥5 likely effective drugs) (29-31). Optimal MDR-TB treatment requires 244 continued, unrestricted access to high quality medications; in a recent survey we documented that this was 245 not the case in many clinics in EE (32). In agreement with this, linezolid, bedaquiline and delamanid were 246 generally not used although widespread use in the current context raises significant opportunities for these 247 drugs to be rapidly lost due to the emergence of resistance. 248
There is now solid evidence that ART should be initiated shortly after TB diagnosis, especially in patients 249 with MDR-TB and those with CD4 cell counts below 50 cells/mm 3 (33-36). In our study, patients were 250 severely immunosuppressed, and two-thirds of those who remained under follow-up at three months had 251 initiated ART. However, less than 20% had documented suppressed viral loads at any time which is well 252 short of the WHO goal of virological suppression in 90% of patients receiving ART (37). 253
We documented a mortality rate of nearly 50% within the first two years following initiation of TB 254 treatment, which is similar to the mortality observed in a retrospective study from our group of HIV-255 patients with MDR-TB in EE which was conducted in the period 2004-2006 (14) . Retrospective African 256 studies reported mortality rates among HIV-positive patients with MDR-TB of 15-31% (38-40) and a meta-257 analysis of outcomes found a pooled mortality rate of 38% (41). The vast majority of deaths in our 258 retrospective cohort were due to TB (42), which underscores the particular need for high-quality TB 259 management for people with HIV. Other circumstances may have played a role in determining outcome of 260 MDR-TB patients in EE. A disintegrated health care system with separated TB and HIV management remains 261 common (32) and is likely to contribute to poor coordination of care to this often very vulnerable patient 262 population. In particular, opioid substitution therapy for IDU is severely restricted or even prohibited in 263 some countries despite documented positive effects on adherence to treatment and health care in general 264 (43) . 265
Our observational study has several limitations including the intrinsic risk of selection bias. The participating 266 clinics were primarily located in major cities and may not be representative of all clinics across EE. DST was 267 done locally and methods for performing DSTs varied between clinics, and when calculating the number of 268 active drugs, we counted all drugs as equally effective which is likely to be an over-simplification. A large 269 number of patients had missing DST results, CD4 cell counts and HIV-RNA measurements precluding a more 270 robust evaluation of immune-virological outcomes. Nonetheless, the circumstances described reflect the 271 difficulties for many HIV and TB clinicians working in EE, although substantial regional variability in the 272 prevalence of MDR-TB and availability of DST, TB and ART drugs, and HIV-RNA measurements exists (12). 273
Due to limited number of patients with MDR-TB we did not assess intraregional variability. (52) 22 ( 
